1. Absence of association between IL-28B gene polymorphism (rs SNP) and sustained virological response in Iranian patients with chronic Hepatitis C

2. Introduction Epidemiology Chronic Hepatitis C
Ref:Hepatitis C VirusesGenomes and Molecular Biology PhD. Lilly Research Laboratories, Indianapolis, USA Norfolk (UK): Horizon Bioscience; 2006.ISBN-10: ISBN-13:

3. Introduction Risk Factors for Developing Chronic HCV Infection
Ref: Stephen L. Chen, International Journal of Medical Sciences,2006

4. Introduction Treatment: The cure rate depends on several factors:
HCV genotype, past treatment experience, eligibility to take the drug interferon.
currently recommended regimen:
Is based on the use of pegylated interferon (PEG-IFN) combined with ribavirin (RBV) for 24 to 72.

5. Introduction
Interleukin 28B (interferon-λ 3):

6. The SNP is located on chromosome 19q13 Rs
The SNP is located on chromosome 19q13
It is 3 kilobases downstream of the interleukin-28B
SNP genotypes: TT TG GG
In many studies it has been proved that “G” allele is strongly associated with NVR (none virological response).
Ref:Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype, Xiaoyan Guo ,China,2009

7. Materials & Methods Our research aimed at:
Identifying rs SNP polymorphism assotiation with the response to Hepatitis C treatment among infected Iranians.

8. Materials & Methods
71 +SVR
22 -SVR
57 Healthy individua

9. Materials & Methods Statistic Analysis PCR RFLP BsemI DNA Extraction
Electrophoresis

10. Electrophoresis of PCR products:
Results
Electrophoresis of PCR products:
400bp
Negative
control
SVR(+)
SVR(-) 1 2 3 4 5

11. Electrophoresis of digested PCR products:
Results
Electrophoresis of digested PCR products: M 1 2 3 4 5 6
400
234
166

12. Genotype frequency of case and control groups
Results
Genotype frequency of case and control groups
Host genotype
Control(n(%))
Case(n(%))
P-value
OR**
95% CI***
TT*
43(75)
53(57)
0.06 TG
13(23)
33(35)
2.06 GG
1(2)
7(8)
0.11
5.67 T* 99
139 G 15 47
0.013
2.23

13. Genotype frequency of case and control groups
Results
Genotype frequency of case and control groups

14. Results: Genotype frequency among case group
Host genotype
SVR+
N (%)
SVR-
Pvalue
Or**
95%ci***
TT*
46(65)
7(32)
0.01 TG
19(27)
14(64)
0.003
0.20 GG
6(8)
1(4)
0.93
0.91 T*
111 28 G 31 16
0.055
.489

15. Genotype frequency among positive SVR and non-SVR
Results
Genotype frequency among positive SVR and non-SVR

16. They showed that 91% of GG allele carriers did not achieve SVR.
Discussion
Spain , 2010
Positive SVR:
TT:83.5%
TG:10.5%
GG:6%
They showed that 91% of GG allele carriers did not achieve SVR.

17. Discussion Germany, 2010 Positive SVR: TT:80.5% GG:87.5%
They showed no correlation between rs polymorphism and SVR.
In our study we concluded the rate of SVR as :
TT:86%
GG: 85%

18. Discussion
Brazil, 2013
Frequency of T allele among Hepatitis C patients was 63.3% whereas 75.5% among Healthy people.
G allele was 1.7 time higher between infected people.
They did not find any correlation between the treatment and the polymorphism neither did we.

19. Conclusion
Totally 150 people including 93 HCV infected patients and 57 healthy individuals entered the study.
G allele can increase the risk of Hepatitis C disease 2.23 time.
We did not find significant difference between case group and control group in term of rs genotypes distribution.
There is no correlation between rs polymorphism and SVR.

20. Future prospective Studying more samples in Iranian population.
Considering more HCV genotypes if possible.
Conducting the same research on other related genes such as TGFβ and TNFα.

21. Acknowledgment
Dr.Seyed Mehdi sadat, Molecular Genetics assistant professor
Dr.Mehri Nikbin, Infectiuos diseases specialist
Hepatitis & Aids Department of Pastuer Institiue of Iran

22. Thank you for your attention!
It Strongly Can Overcome Medical Struggles
iscoms
Thank you for your attention!